Cargando…

Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians

Detalles Bibliográficos
Autores principales:	Dieterle, Martin Philipp, Mostufi-Zadeh-Haghighi, Gila, Kus, Jan Wilhelm, Wippel, Christopher, Brugger, Zacharias, Miething, Cornelius, Wäsch, Ralph, Engelhardt, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640491/ https://www.ncbi.nlm.nih.gov/pubmed/37710140 http://dx.doi.org/10.1007/s00277-023-05451-8

Ejemplares similares

Teclistamab: First Approval
por: Kang, Connie
Publicado: (2022)

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS
por: Frerichs, Kristine, et al.
Publicado: (2023)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
por: Searle, E., et al.
Publicado: (2023)

Functional Characterization of Transforming Growth Factor-β Signaling in Dasatinib Resistance and Pre-BCR(+) Acute Lymphoblastic Leukemia
por: Mostufi-Zadeh-Haghighi, Gila, et al.
Publicado: (2023)

Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score
por: Kleber, M, et al.
Publicado: (2011)

Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma
por: Leung, Nelson, et al.
Publicado: (2023)

Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody
por: Pan, Darren, et al.
Publicado: (2023)

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY
por: Rodriguez-Otero, P, et al.
Publicado: (2022)

Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
por: Hua, Gwen, et al.
Publicado: (2023)

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
por: Krishnan, Amrita, et al.
Publicado: (2023)

Safe and feasible outcomes of cholecystectomy in extremely elderly patients (octogenarians vs. nonagenarians)
por: Kim, Su Min, et al.
Publicado: (2021)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Krishnan, A., et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
por: Miao, Xin, et al.
Publicado: (2023)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Laparoscopic Colorectal Resection in Octogenarian Patients: Is it Safe? A Systematic Review and Meta-Analysis
por: Xie, Minghao, et al.
Publicado: (2015)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
por: Offner, Fritz, et al.
Publicado: (2023)

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY
por: Tan, Carlyn, et al.
Publicado: (2023)

Neurosurgery in an octogenarian with dementia
por: Andrew, Gemma, et al.
Publicado: (2011)

Radical cystectomy in octogenarians
por: Rawal, Sudhir, et al.
Publicado: (2012)

Cardiac surgery in octogenarians
por: Nussbacher, A, et al.
Publicado: (2005)

REWIND Diabetes for Octogenarians
por: Geberhiwot, Tarekegn
Publicado: (2021)

The Soul of Octogenarian BJORL
por: Neto, Silvio Caldas
Publicado: (2015)

Dermoscopy of very small basal cell carcinoma (≤3 mm)()
por: Arias-Rodriguez, Camilo, et al.
Publicado: (2023)

Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers
por: Frank, Benedikt, et al.
Publicado: (2022)

Double-vessel very late stent thrombosis following Resolute Onyx zotarolimus eluting stents implantation in an octogenarian
por: Kassimis, George, et al.
Publicado: (2018)

Very Late-Onset Systemic Lupus Erythematosus as Unusual Cause of Reversible Functional and Cognitive Impairments in an Octogenarian Patient
por: de Montjoye, Stéphanie, et al.
Publicado: (2020)

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Mateos, M. V., et al.
Publicado: (2022)

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
por: Rosinol, L., et al.
Publicado: (2022)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
por: Bhutani, Manisha, et al.
Publicado: (2023)

Aortic valve replacement in octogenarians
por: Bose, Amal K, et al.
Publicado: (2007)

Outcomes of Laparoscopic Cholecystectomy in Octogenarians
por: Marcari, Rafael S., et al.
Publicado: (2012)

ALCAPA in an Octogenarian Woman: An Enigma
por: Sinha, Santosh Kumar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cglcdvt471e0s5b0q4j6ecu4or